| B cells and tertiary lymphoid structures promote immunotherapy response BA Helmink, SM Reddy, J Gao, S Zhang, R Basar, R Thakur, K Yizhak, ... Nature 577 (7791), 549-555, 2020 | 1664 | 2020 |
| Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial HA Tawbi, M Burgess, V Bolejack, BA Van Tine, SM Schuetze, J Hu, ... The Lancet Oncology 18 (11), 1493-1501, 2017 | 1112 | 2017 |
| Induction of CD8+ T-cell responses against novel glioma–associated antigen peptides and clinical activity by vaccinations with α-type 1 polarized dendritic cells and … H Okada, P Kalinski, R Ueda, A Hoji, G Kohanbash, TE Donegan, ... Journal of clinical oncology 29 (3), 330, 2011 | 677 | 2011 |
| A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four α-fetoprotein peptides LH Butterfield, A Ribas, VB Dissette, Y Lee, JQ Yang, P De la Rocha, ... Clinical Cancer Research 12 (9), 2817-2825, 2006 | 591 | 2006 |
| Immunotherapy of cancer in 2012 JM Kirkwood, LH Butterfield, AA Tarhini, H Zarour, P Kalinski, S Ferrone CA: a cancer journal for clinicians 62 (5), 309-335, 2012 | 583 | 2012 |
| T-cell responses to HLA-A* 0201 immunodominant peptides derived from α-fetoprotein in patients with hepatocellular cancer LH Butterfield, A Ribas, WS Meng, VB Dissette, S Amarnani, HT Vu, ... Clinical Cancer Research 9 (16), 5902-5908, 2003 | 470 | 2003 |
| A comparison of gene transfer methods in human dendritic cells. JF Arthur, LH Butterfield, MD Roth, LA Bui, SM Kiertscher, R Lau, ... Cancer Gene Therapy 4 (1), 17-25, 1997 | 418 | 1997 |
| Current developments in cancer vaccines and cellular immunotherapy A Ribas, LH Butterfield, JA Glaspy, JS Economou Journal of clinical oncology 21 (12), 2415-2432, 2003 | 414 | 2003 |
| Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial FS Hodi, S Lee, DF McDermott, UN Rao, LH Butterfield, AA Tarhini, ... Jama 312 (17), 1744-1753, 2014 | 393 | 2014 |
| Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma AA Tarhini, H Zahoor, Y Lin, U Malhotra, C Sander, LH Butterfield, ... Journal for immunotherapy of cancer 3, 1-6, 2015 | 355 | 2015 |
| Soluble PD-L1 as a biomarker in malignant melanoma treated with checkpoint blockade J Zhou, KM Mahoney, A Giobbie-Hurder, F Zhao, S Lee, X Liao, S Rodig, ... Cancer immunology research 5 (6), 480-492, 2017 | 327 | 2017 |
| Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma LH Butterfield, A Ribas, VB Dissette, SN Amarnani, HT Vu, D Oseguera, ... Clinical Cancer Research 9 (3), 998-1008, 2003 | 321 | 2003 |
| Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab AA Tarhini, H Edington, LH Butterfield, Y Lin, Y Shuai, H Tawbi, C Sander, ... PloS one 9 (2), e87705, 2014 | 319 | 2014 |
| Dendritic cell–based cancer vaccines PM Santos, LH Butterfield The Journal of Immunology 200 (2), 443-449, 2018 | 318 | 2018 |
| Cancer vaccines LH Butterfield Bmj 350, 2015 | 293 | 2015 |
| Next generation of immunotherapy for melanoma JM Kirkwood, AA Tarhini, MC Panelli, SJ Moschos, HM Zarour, ... Journal of Clinical Oncology 26 (20), 3445-3455, 2008 | 276 | 2008 |
| Generation of human T-cell responses to an HLA-A2. 1-restricted peptide epitope derived from α-fetoprotein LH Butterfield, A Koh, W Meng, CM Vollmer, A Ribas, V Dissette, E Lee, ... Cancer research 59 (13), 3134-3142, 1999 | 263 | 1999 |
| Novel technologies and emerging biomarkers for personalized cancer immunotherapy J Yuan, PS Hegde, R Clynes, PG Foukas, A Harari, TO Kleen, P Kvistborg, ... Journal for immunotherapy of cancer 4, 1-25, 2016 | 262 | 2016 |
| Genetic immunization for the melanoma antigen MART-1/Melan-A using recombinant adenovirus-transduced murine dendritic cells A Ribas, LH Butterfield, WH McBride, SM Jilani, LA Bui, CM Vollmer, ... Cancer Research 57 (14), 2865-2869, 1997 | 238 | 1997 |
| α-Fetoprotein-specific genetic immunotherapy for hepatocellular carcinoma CM Vollmer Jr, FC Eilber, LH Butterfield, A Ribas, VB Dissette, A Koh, ... Cancer Research 59 (13), 3064-3067, 1999 | 232 | 1999 |
Antoni RibasUCLAVerified email at mednet.ucla.edu
